Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 20 | 2026 | 371 | 4.650 |
Why?
|
| Brain Neoplasms | 26 | 2026 | 1306 | 4.180 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2026 | 79 | 1.550 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2026 | 1272 | 1.400 |
Why?
|
| Astrocytoma | 3 | 2026 | 101 | 1.360 |
Why?
|
| Glioma | 4 | 2022 | 494 | 1.360 |
Why?
|
| Meningeal Neoplasms | 7 | 2026 | 220 | 1.260 |
Why?
|
| Meningioma | 5 | 2026 | 151 | 0.780 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1129 | 0.640 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 195 | 0.640 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2015 | 108 | 0.590 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 54 | 0.570 |
Why?
|
| Research Design | 2 | 2023 | 716 | 0.550 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 13 | 0.540 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 210 | 0.500 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 395 | 0.500 |
Why?
|
| Ganglioglioma | 1 | 2016 | 20 | 0.480 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2025 | 3763 | 0.450 |
Why?
|
| Blindness | 1 | 2015 | 70 | 0.430 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 523 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 570 | 0.410 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 98 | 0.400 |
Why?
|
| West Nile virus | 1 | 2015 | 122 | 0.390 |
Why?
|
| West Nile Fever | 1 | 2015 | 145 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 227 | 0.380 |
Why?
|
| Humans | 49 | 2026 | 131163 | 0.380 |
Why?
|
| Neuroimaging | 1 | 2015 | 385 | 0.340 |
Why?
|
| Mutation | 8 | 2026 | 6099 | 0.340 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 26 | 0.340 |
Why?
|
| Adult | 21 | 2026 | 31282 | 0.340 |
Why?
|
| Body Height | 2 | 2021 | 192 | 0.310 |
Why?
|
| Aged | 16 | 2026 | 21025 | 0.310 |
Why?
|
| Neoplasms | 4 | 2019 | 3016 | 0.300 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 248 | 0.300 |
Why?
|
| Middle Aged | 21 | 2026 | 28601 | 0.280 |
Why?
|
| Retrospective Studies | 15 | 2024 | 17753 | 0.260 |
Why?
|
| Bevacizumab | 3 | 2017 | 59 | 0.260 |
Why?
|
| Male | 23 | 2026 | 64957 | 0.230 |
Why?
|
| Female | 25 | 2026 | 70963 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2026 | 136 | 0.220 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1216 | 0.220 |
Why?
|
| Young Adult | 9 | 2021 | 10103 | 0.210 |
Why?
|
| Benchmarking | 1 | 2025 | 137 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1826 | 0.210 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2023 | 28 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 587 | 0.180 |
Why?
|
| Cerebellar Nuclei | 1 | 2022 | 11 | 0.180 |
Why?
|
| Olivary Nucleus | 1 | 2022 | 14 | 0.180 |
Why?
|
| Hypertrophy | 1 | 2022 | 100 | 0.180 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 80 | 0.180 |
Why?
|
| Radiotherapy | 2 | 2019 | 119 | 0.180 |
Why?
|
| Melanoma | 2 | 2022 | 931 | 0.170 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 126 | 0.170 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 130 | 0.170 |
Why?
|
| Ependymoma | 1 | 2022 | 137 | 0.170 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2021 | 8 | 0.170 |
Why?
|
| JC Virus | 1 | 2021 | 26 | 0.170 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 48 | 0.160 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 39 | 0.160 |
Why?
|
| Electroencephalography | 2 | 2016 | 863 | 0.160 |
Why?
|
| Seizures | 1 | 2026 | 890 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6797 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2019 | 1483 | 0.160 |
Why?
|
| Microbiota | 1 | 2025 | 438 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 369 | 0.160 |
Why?
|
| Prognosis | 5 | 2026 | 4886 | 0.150 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2019 | 22 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2019 | 5 | 0.150 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 25 | 0.150 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 915 | 0.150 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 13 | 0.150 |
Why?
|
| Optic Nerve Glioma | 1 | 2019 | 22 | 0.140 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 15 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 81 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 83 | 0.140 |
Why?
|
| Telomerase | 1 | 2019 | 154 | 0.140 |
Why?
|
| Algorithms | 1 | 2025 | 1680 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2018 | 58 | 0.140 |
Why?
|
| Insurance, Health | 1 | 2019 | 146 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2026 | 1586 | 0.130 |
Why?
|
| Erdheim-Chester Disease | 1 | 2017 | 28 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 633 | 0.130 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 14 | 0.130 |
Why?
|
| Third Ventricle | 1 | 2017 | 24 | 0.130 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2017 | 21 | 0.130 |
Why?
|
| Hemangioma, Cavernous | 1 | 2017 | 19 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 905 | 0.120 |
Why?
|
| Pandemics | 1 | 2024 | 1118 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 127 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 97 | 0.120 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 322 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2017 | 255 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1071 | 0.120 |
Why?
|
| Gliosarcoma | 1 | 2015 | 7 | 0.120 |
Why?
|
| Survival Rate | 2 | 2018 | 2114 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1207 | 0.110 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 233 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2017 | 245 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2019 | 12936 | 0.110 |
Why?
|
| Incidence | 3 | 2020 | 3360 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2904 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 395 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1029 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2021 | 6459 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2021 | 5063 | 0.100 |
Why?
|
| Wound Healing | 1 | 2015 | 490 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2065 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 680 | 0.080 |
Why?
|
| Israel | 2 | 2021 | 44 | 0.080 |
Why?
|
| Time Factors | 3 | 2018 | 6196 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1075 | 0.080 |
Why?
|
| Risk Factors | 4 | 2021 | 11074 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1545 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 97 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 20987 | 0.070 |
Why?
|
| Oligodendroglioma | 1 | 2026 | 25 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2026 | 116 | 0.060 |
Why?
|
| Neoplasm Grading | 1 | 2026 | 274 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5196 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2026 | 825 | 0.050 |
Why?
|
| Age Factors | 2 | 2019 | 2825 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 613 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2022 | 37 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 111 | 0.040 |
Why?
|
| Bacteria | 1 | 2025 | 521 | 0.040 |
Why?
|
| Dimethyl Fumarate | 1 | 2021 | 10 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 217 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3711 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 194 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2022 | 210 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 125 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 564 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 71 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 562 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 122 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 387 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 760 | 0.030 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2017 | 6 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 34 | 0.030 |
Why?
|
| Dura Mater | 1 | 2017 | 24 | 0.030 |
Why?
|
| Linear Models | 1 | 2019 | 688 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2019 | 191 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 161 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 352 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 663 | 0.030 |
Why?
|
| Headache | 1 | 2017 | 107 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1356 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 190 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 667 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 410 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 40 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 99 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 713 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 102 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1717 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1267 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 286 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 387 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 567 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1634 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 821 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1490 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 722 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2200 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2085 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 844 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7512 | 0.010 |
Why?
|
| Brain | 1 | 2017 | 3175 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 33912 | 0.010 |
Why?
|